Navigation Links
Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
Date:5/24/2011

acute gouty arthritis(1,2). Patients had suffered from three or more gouty arthritis attacks in the previous 12 months and were either unresponsive or intolerant to common therapies like NSAIDs or colchicine, or these treatments were contraindicated. Patients were randomized to receive a single dose of ACZ885 150 milligrams (mg) via subcutaneous (s.c.) injection or TA 40 mg via intramuscular (i.m.) injection(1,2). In the case of a new attack, patients received a new dose of the same treatment they were randomized to at baseline.

Both studies had the same two primary endpoints: pain intensity at 72 hours post-dose; and time to the first new gouty arthritis attack(1,2). Pain in the affected joint was measured according to an internationally recognized pain scale, the Visual Analog Scale (VAS).

In one study, patients treated with ACZ885 had significantly lower mean pain scores at 72 hrs, with pain intensity decreasing from 73.3 mm at baseline to 28.1 mm for ACZ885 vs. 74.8 mm at baseline to 39.5 mm for TA (p=0.0005)(1,16). Similarly, patients in the other study receiving ACZ885 had significantly lower mean pain scores at 72 hrs, with pain intensity decreasing from 74.9 mm at baseline to 22.1 mm for ACZ885 vs. 73.6 mm at baseline to 31.9 mm for TA (p=0.0018)(17).

The number of patients with new attacks across both studies was also significantly reduced with ACZ885 compared to TA(2). In the first study, nearly twice as many patients experienced a new gouty arthritis attack in the TA group compared to ACZ885 (40 vs. 21 patients respectively [p=0.0061])(18). In addition, in the second study nearly three times as many patients in the TA group experienced a new attack compared to ACZ885 (42 vs. 15 patients respectively [p=0.0001])(18). In the previous year, patients in both studies suffered an average of at least six attacks (6.5 for ACZ885 and seven for TA in study one; and 6.5 and 5.9 respectively in study two)(16,17).

ACZ885 was generally wel
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  BioElectronics Corporation (OTC Pink: BIEL), maker of ... Andrew J. Whelan , President will be interviewed ... Business" at 9am EDT on Wednesday, August 5 th ... http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ Mr. ... the company,s flagship product, ActiPatch Therapy, is achieving in ...
(Date:8/3/2015)... Aug. 3, 2015  CytomX, a biopharmaceutical company ... today announced the promotion of several members of ... , who previously served as vice president of ... to senior vice president of corporate development and ... positions as the vice president of business development ...
(Date:8/3/2015)... , Aug. 3, 2015 Immune Pharmaceuticals, ... CEO, Dr. Daniel Teper , will present live ... August 6, 2015 TIME:   11:30AM EDT LINK:    ... live, interactive online event where investors are invited to ... the presentation hall as well as the association,s "virtual ...
Breaking Medicine Technology:UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2
... Feb. 19, 2011 Genoptix, Inc. (Nasdaq: ... a memorandum of understanding ("MOU") providing for the settlement ... the Superior Court of the State of California, San ... Genoptix, Inc., Case No. 37-2011-00050762-CU-BT-NC, (2) Schwitters v. Genoptix, ...
... 18, 2011 TLC Vision announced today its plans for ... in San Diego.  Internationally recognized as leaders in field of ... Tanzer MD will lend their surgical skill and expertise to ... center will continue to be at the forefront of working ...
Cached Medicine Technology:Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 2Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 3Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 4Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 5Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 6Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 7Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 8Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 9Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 10Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits 11TLC Vision Announces TLC Laser Eye Center San Diego 2
(Date:8/4/2015)... ... August 04, 2015 , ... Lightning Labels is ... Denver facility that will usher in a new standard of sticker and label-making ... more effectively meet its twin objectives of quality and quantity without compromising the ...
(Date:8/4/2015)... ... ... Following last month’s successful rollout of its client video series, ACE announces the ... Setting, and The Importance of PVI Accreditation. , In The Benefits of Cath ... Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions in Las Vegas, NV, Chandan Devireddy, MD, ...
(Date:8/3/2015)... ... August 04, 2015 , ... ... Holt as a 2015-2016 inductee into the NAPW VIP Woman of the ... With more than 700,000 members and over 200 operating Local Chapters, NAPW is ...
(Date:8/3/2015)... ... August 04, 2015 , ... Keeping strong to their ... professionals, HomeCEUConnection.com today announced extra savings on Florida Physical Therapy continuing education ... big savings on Physical Therapy Flex packages by entering the promo ...
(Date:8/3/2015)... Indianapolis, Indiana (PRWEB) , ... August 03, 2015 ... ... ) throughout Livingston and Putnam counties. As a family owned and operated ... all septic matters. They are a leader in septic installations because of ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 2Health News:Accreditation for Cardiovascular Excellence (ACE) Clients Explain Benefits of ACE Accreditation 3Health News:National Association of Professional Women Inducts Armethia Holt, CEO at AA&G Group Homes, LLC, Into its VIP Woman of the Year Circle 2Health News:Elite Online CE Provider Offers Discounted Flexible Packages to Meet Florida Physical Therapy Continuing Education Requirements 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3
... that has enhanced public understanding of biomedical researchWASHINGTON, ... (FBR) announced today it is accepting entries for ... The awards, named after FBR,s late chairman, ... reporting has enhanced public understanding of how the ...
... April 3 AstraZeneca (NYSE: AZN ) ... Drug Administration (FDA) posted to its web site -- ... 8, 2009 Psychopharmacologic Drugs Advisory Committee (PDAC) meeting. The ... efficacy data provided in supplemental new drug applications (sNDA) ...
... researchers say , , FRIDAY, April 3 (HealthDay News) -- ... insights into multiple sclerosis and other afflictions of the ... looking into why pregnant cats on a special diet ... including paralysis and vision, University of Wisconsin-Madison researchers found ...
... stock jeopardize shareholder interests?TEQUESTA, Fla., April 3 In ... and the Board of Directors of Energy Partners, LTD ... (CCC), personally holding a quarter million shares as well ... concern over a proposed bond buyout of the company,s ...
... Pass Bill to Protect Patient Access WASHINGTON, April 3 ... osteoporosis testing and reduce the physical and economic burden ... "Medicare Fracture Prevention and Osteoporosis Testing Act of 2009," ... and Olympia Snowe (R-ME) introduced the Senate version and ...
... 3 First Choice Professionals, LLC., today announced the ... Health Integration Solution ( THIS ). ... has joined forces with TIBCO Software Inc. (Nasdaq: ... brokering, SOA integration, and complex event processing. The partnership ...
Cached Medicine News:Health News:Foundation for Biomedical Research Announces Michael E. DeBakey Journalism Awards 2Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 2Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 3Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 4Health News:FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site 5Health News:Cat Food-Linked Illness Yields Clues to MS 2Health News:Access to Osteoporosis Testing for Americans in Jeopardy 2Health News:Access to Osteoporosis Testing for Americans in Jeopardy 3Health News:Access to Osteoporosis Testing for Americans in Jeopardy 4Health News:Access to Osteoporosis Testing for Americans in Jeopardy 5Health News:FCP Announces Total Healthcare Integration Solution (THIS) Powered by TIBCO 2
... device is a qualitative immunoassay ... inspect the,overdose usage of cocaine ... metabolite of,cocaine, in human urine ... 300 ng/mL. It is for ...
... test is an immunochromatography based one ... for qualitative determination of Benzodiazepines and ... a cut-off level of 300 ng/mL ... in the point of care location ...
... 2000, Applied Biosystems introduced the completely ... M 3100 Genetic Analyzer.,Now the innovative ... available in our new four-capillary ABI ... to-medium-throughput laboratory needs, the fully automated ...
... AcT diff2 delivers performance, ... office labs and smaller laboratories. ... that offers a small sample ... closed analysis modes, a wide ...
Medicine Products: